A detailed history of Tekla Capital Management LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 309,613 shares of ALKS stock, worth $7.46 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
309,613
Previous 309,613 -0.0%
Holding current value
$7.46 Million
Previous $8.73 Million 11.03%
% of portfolio
0.38%
Previous 0.33%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 01, 2022

BUY
$22.0 - $31.87 $2.63 Million - $3.81 Million
119,491 Added 62.85%
309,613 $6.91 Million
Q1 2022

May 13, 2022

SELL
$23.07 - $27.99 $2.01 Million - $2.44 Million
-87,187 Reduced 31.44%
190,122 $5 Million
Q4 2021

Feb 14, 2022

SELL
$21.47 - $32.08 $2.07 Million - $3.1 Million
-96,515 Reduced 25.82%
277,309 $6.45 Million
Q3 2021

Nov 12, 2021

BUY
$23.37 - $32.13 $8.74 Million - $12 Million
373,824 New
373,824 $11.5 Million
Q2 2021

Aug 13, 2021

SELL
$18.78 - $25.15 $3.19 Million - $4.27 Million
-169,930 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$13.06 - $21.24 $367,221 - $597,226
-28,118 Reduced 14.2%
169,930 $2.45 Million
Q1 2019

May 14, 2019

BUY
$28.4 - $36.49 $1.33 Million - $1.71 Million
46,765 Added 30.91%
198,048 $7.23 Million
Q4 2018

Feb 13, 2019

SELL
$27.94 - $44.61 $552,066 - $881,448
-19,759 Reduced 11.55%
151,283 $4.46 Million
Q2 2018

Aug 13, 2018

SELL
$40.56 - $51.36 $1.59 Million - $2.01 Million
-39,140 Reduced 18.62%
171,042 $7.04 Million
Q1 2018

May 14, 2018

BUY
$53.61 - $67.26 $3.54 Million - $4.45 Million
66,110 Added 45.89%
210,182 $12.2 Million
Q4 2017

Feb 14, 2018

BUY
$47.69 - $55.39 $6.87 Million - $7.98 Million
144,072
144,072 $7.89 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $3.96B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.